ArticleVirchows Archiv : an international journal of pathology2026
Nectin-4 expression in vulvar squamous cell carcinoma.
Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Evaluation of HER2 and Nectin-4 Expression in Primary Vaginal Cancers.International journal of molecular sciences · 2026Article
- Expression of nectin-4 in squamous cell carcinoma of prostate: a pilot study and case report.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Therapy options for women with vulvar squamous cell carcinoma (VSCC) are limited. New strategies such as immune checkpoint inhibitors (ICI) or antibody-drug conjugates (ADC) are lacking. One potential target for the ADC Enfortumab Vedotin (EV) is Nectin-4. EV has been successfully used to treat metastatic urothelial carcinoma (mUC). Currently, there is limited data on the expression of Nectin-4 for VSCC. Our aim was therefore to investigate the expression of Nectin-4 in women with VSCC. In total, 219 formalin-fixed paraffin-embedded tissue (FFPE) samples of primary VSCC were collected between 2000 and 2021. A next generation tissue microarray (ngTMA) was constructed. The assessment of Nectin-4 expression was performed through the implementation of immunohistochemistry (IHC). We also performed NECTIN-4 fluorescence in situ hybridization (FISH) to evaluate amplification of Nectin-4. The median Nectin-4 H-score for membranous expression was 22.5, with 32.4% of VSCCs exhibiting moderate to strong expression. We could not show that Nectin-4 H-score (membranous) significantly influenced overall survival in addition to other prognostic factors. The rates of regional lymph node metastases, lymphatic vascular space involvement, G3-Grading, perineural sheath invasion and p16-/p53+ were highest in Nectin-4-negative VSCC. 28.8% of recurrent VSCC had moderate or strong expression of Nectin-4. None of the investigated VSCC (primary or recurrent) showed amplification of Nectin-4 in contrast to mUC. Nectin-4 could be a potential target in the therapy of women with VSCC. Further (pre-)clinical data is needed to evaluate the use of EV in therapy of women with VSCC.
Indexed as
Identifiers
41888429What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.